Overview
nyra health builds a digital therapy platform for neurological rehabilitation. Its main product, the myReha app, is a CE-certified medical device that delivers individualized therapy plans for patients with speech and cognitive impairments, usable in clinics or at home, while the nyra insights web platform provides analytics and clinician workflow. The system uses AI to create personalized, multimodal therapy plans and lets therapists monitor progress and adjust care as patients complete exercises in the app, connecting clinic and home care. The goal is to improve the efficiency and effectiveness of neurological therapy with adaptive treatment and robust clinician analytics for better patient outcomes.
Work here?Claim your company
Simplify's take
What believers are saying
- The 2026 MDR Class IIa recertification lowers procurement friction for hospitals and insurers.
- nyra insights automates documentation, increasing therapist throughput and clinic adoption.
- Existing reimbursement across Germany, Austria, and Switzerland supports expansion without pure pilot economics.
What critics are saying
- German reimbursement concentration makes DiGA policy changes an existential revenue shock.
- US launch in 2026 with a pharma partner adds regulatory, integration, and sales risk.
- Competing digital neurorehab vendors can copy features unless nyra proves superior outcomes fast.
What makes nyra health unique
- myReha combines CE-marked therapy, clinician analytics, and home use in one workflow.
- Nyra Health secured €20 million from Armira Growth on 2026-02-24.
- By 2026, myReha reached 100-plus clinics and 28 reimbursing insurers.
Help us improve and share your feedback! Did you find this helpful?